HighGravityData

CVS Health — Oct 17, 2024 release

Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001193125-24-239193
Open on SEC.gov ↗
Showing in the filing
Weighted average diluted shares outstanding
“1,259”
Period
Q3 FY2024
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 6
Adjusted EPS for Q3 FY2024
“$1.05” – “$1.10”
Adjusted EPS (preliminary) for Q3 FY2024
“$1.05 to $1.10”
GAAP diluted EPS for Q3 FY2024
“$0.03” – “$0.08”
GAAP diluted EPS (preliminary) for Q3 FY2024
“$0.03 to $0.08”
Medical Benefit Ratio (MBR) for Q3 FY2024
“approximately 95.2%”
Weighted average diluted shares outstanding for Q3 FY2024
“1,259”
Exhibit 99.1 · the passage around this item
… earlier in the release
The following are reconciliations of projected net income attributable to CVS Health to adjusted income attributable to CVS Health and projected GAAP diluted EPS to Adjusted EPS:        Three Months Ended September 30, 2024        Low      High   In millions, except per share amounts    Total Company      Per Common Share      Total Company      Per Common Share   Net income attributable to CVS Health (GAAP measure)    $ 40      $ 0.03      $ 103      $ 0.08   Amortization of intangible assets      507        0.40        507        0.40   Net realized capital gains      (19 )       (0.02 )       (19 )       (0.02 )  Acquisition-related integration costs (1)      41        0.03        41        0.03   Restructuring charges (2)      1,169        0.93        1,169        0.93   Office real estate optimization charges (3)      17        0.01        17        0.01   Tax impact of non-GAAP adjustments (4)      (433 )       (0.33 )       (433 )       (0.33 )                                      Adjusted income attributable to CVS Health    $ 1,322      $ 1.05      $ 1,385      $ 1.10                                       Weighted average diluted shares outstanding         1,259           1,259     (1) During the three months ended September 30, 2024, the acquisition-related integration costs relate to the acquisitions of Signify Health and Oak Street Health.   (2) During the three months ended September 30, 2024, the restructuring charges are primarily comprised of a store impairment charge, other asset impairment and related charges associated with the discontinuation of certain non-core assets, as well as corporate workforce optimization costs, including severance and employee-related costs. During the third quarter of 2024, the Company developed an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it would close 271 additional retail stores, and, accordingly, it recorded a store impairment charge to write down the associated operating lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.